Bristol-Myers Squibb Company (NYSE: BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'February 6, 2018 6:51 AM Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1cFebruary 5, 2018 7:02 AM Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) February 5, 2018 6:59 AM